AROA BIOSURGERY LIMITED (ARX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ARX - AROA BIOSURGERY LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.93
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.635

20 Nov
2024

-0.015

OPEN

$0.65

-2.31%

HIGH

$0.65

1,197,838

LOW

$0.63

TARGET
$0.975 53.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
ARX: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 0.6 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 117.9 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.0 M
Book Value Per Share xxxxxxxxxxxxxxx25.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.8 M
Net Profit Margin xxxxxxxxxxxxxxx-15.39 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.81 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.14 %
Return on Assets xxxxxxxxxxxxxxx-9.35 %
Return on Equity xxxxxxxxxxxxxxx-10.81 %
Return on Total Capital xxxxxxxxxxxxxxx-11.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx28 M
Price To Book Value xxxxxxxxxxxxxxx2.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.5 M
Capex % of Sales xxxxxxxxxxxxxxx10.11 %
Cost of Goods Sold xxxxxxxxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx66 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

23/10/2024

1

Add

$1.05

65.35%

Morgans observes a "solid" 2Q25 cash flow report for Aroa Biosurgery including growth in receipts of 35% on a year earlier with operating cash flow of NZ$1.2m.

Management reiterated FY25 guidance of growth in sales of 26% at the midpoint and positive EBITDA. 

The analyst highlights the company's US marketing partner, Tela Bio is due to announce 3Q34 results on Nov 7 and Aroa Biosurgery's 1H25 results are expected on Nov 29.

No changes have been made to earnings forecasts. Target price remains at $1.05 and Add rating.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.92 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.68 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

14/08/2024

1

Overweight

$1.00

57.48%

Aroa Biosurgery's US channel partner Tela Bio's June-quarter results missed Wilsons' revenue forecasts but management retained full-year guidance. Revenue for the year rose 11%.

The miss was attributed to a cyber-attack on a nation GPO and hospital customer and the broker says the May incident was resolved within a few weeks and assesses the event will likely have a minimal impact on Aroa Biosurgery.

Wilsons is reviewing its forecasts but doubts any major changes will be required.

Overweight rating and $1 target price retained.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.18 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.75 cents.

Jarden

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

ARX STOCK CHART

FNArena News on ARX

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Nov 13, 2024

Nov 13 2024 - Daily Market Reports
4
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View
5
Rudi’s View: US Earnings & The Election

Oct 31 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps